Several novel targeted agents were recently approved to treat AML, such as the B cell lymphoma 2 (Bcl-2) inhibitor, venetoclax, which is commonly administered in combination with HMAs due to higher efficacy compared to HMAs alone [11,12]. This evidence concerns the gene BCL2 and acute myeloid leukemia.